Congestive Heart Failure (CHF)

Definition

Congestive heart failure (CHF) is a clinical syndrome — not a single disease — characterized by current or prior symptoms and/or signs caused by a structural and/or functional cardiac abnormality. It is corroborated by elevated natriuretic peptides (BNP/NT-proBNP) and/or objective evidence of cardiogenic pulmonary or systemic congestion on imaging or invasive hemodynamic measurements. (ESC Guidelines – Diagnosis and Treatment of Acute and Chronic Heart Failure, p. 5)

Classification by Ejection Fraction

Category	EF	Key Feature
HFrEF (Heart failure with reduced EF)	< 40%	Systolic dysfunction; LV dilated and weak
HFmrEF (mildly reduced EF)	40–49%	Borderline; often ischemic etiology
HFpEF (preserved EF)	≥ 50%	Diastolic dysfunction; stiff LV

NYHA Functional Classification:

Class I — No symptoms with ordinary activity
Class II — Mild symptoms; slight limitation with ordinary activity
Class III — Marked limitation; comfortable only at rest
Class IV — Symptoms at rest; unable to perform any activity without discomfort

Etiology

Most common causes:

Coronary artery disease / ischemic cardiomyopathy (most frequent in the West)
Hypertension → hypertensive cardiomyopathy
Dilated cardiomyopathy (idiopathic, viral, alcoholic, peripartum)
Valvular heart disease (mitral/aortic stenosis or regurgitation)
Diabetes mellitus (diabetic cardiomyopathy)
Arrhythmias (e.g., atrial fibrillation-induced tachycardiomyopathy)

Less common:

Infiltrative diseases (amyloidosis, sarcoidosis, hemochromatosis)
Thyroid disease, high-output states (severe anemia, AV fistula, beriberi)
Cardiotoxins (anthracyclines, trastuzumab, alcohol, cocaine)

Pathophysiology

Primary insult (e.g., MI, pressure overload) → reduced cardiac output
Compensatory mechanisms activated:
- Neurohormonal: RAAS activation → Na/water retention, vasoconstriction
- Sympathetic nervous system activation → tachycardia, increased contractility
- Ventricular remodeling → hypertrophy or dilation
Decompensation: Chronic neurohormonal activation becomes maladaptive → progressive myocyte loss, fibrosis, further chamber dilation
Congestion: Elevated filling pressures → pulmonary congestion (left-sided) and/or systemic venous congestion (right-sided)

Clinical Presentation

Left-sided HF (pulmonary congestion):

Dyspnea on exertion → orthopnea → paroxysmal nocturnal dyspnea (PND)
Pulmonary crackles (rales), S3 gallop
Frothy or pink-tinged sputum in acute pulmonary edema

Right-sided HF (systemic congestion):

Peripheral pitting edema (bilateral, dependent)
Jugular venous distension (JVD)
Hepatomegaly, ascites
Anorexia/nausea (gut edema)

General:

Fatigue, exercise intolerance
Cardiac cachexia (late stage)
Cheyne-Stokes respirations (severe HF)

Diagnosis

Key Investigations

Test	Finding
BNP / NT-proBNP	Elevated; primary biomarker for HF diagnosis
ECG	LVH, Q waves (prior MI), bundle branch block, arrhythmia
Echocardiography	Gold standard: measures EF, wall motion, valve function, filling pressures
Chest X-ray	Cardiomegaly, pulmonary vascular congestion, Kerley B lines, pleural effusions
Labs	CBC, BMP (renal function, electrolytes), LFTs, TFTs, ferritin, iron studies
Coronary angiography	If ischemic etiology suspected

Chest X-ray Findings in CHF

Classic radiographic findings include cardiomegaly, bilateral pleural effusions, pulmonary vascular congestion, and alveolar (bat-wing) pulmonary edema:

Chest X-ray showing CHF findings: cardiomegaly (blue arrow), bilateral pleural effusions with blunted costophrenic angles (red arrows), and pulmonary vascular congestion (yellow arrow)

Management

Acute Decompensated HF

Intervention	Details
Positioning	Sit upright; legs dependent
Oxygen/NIV	Supplemental O₂; CPAP/BiPAP for pulmonary edema
IV Diuretics	Furosemide (loop diuretic) — cornerstone of decongestion
Vasodilators	IV nitroglycerin or nitroprusside if BP allows
Inotropes	Dobutamine, milrinone for cardiogenic shock
Vasopressors	Norepinephrine if hypotensive shock

Chronic HFrEF — Guideline-Directed Medical Therapy (GDMT)

The 2023 ESC Focused Update reinforces a "four pillars" approach for HFrEF (all with mortality benefit):

Pillar	Drug Class	Example Agent
1	ACE inhibitor / ARB / ARNi	Sacubitril/valsartan (preferred over ACEi)
2	Beta-blocker	Carvedilol, bisoprolol, metoprolol succinate
3	MRA (mineralocorticoid receptor antagonist)	Spironolactone, eplerenone
4	SGLT2 inhibitor	Dapagliflozin, empagliflozin

Additional therapies:

Loop diuretics (furosemide) for symptom relief and decongestion
Ivabradine (if HR ≥ 70 bpm on max beta-blocker, sinus rhythm)
Hydralazine + isosorbide dinitrate (if ACEi/ARB/ARNi not tolerated, particularly in Black patients)
Iron replacement (IV ferric carboxymaltose) if iron-deficient

HFpEF

SGLT2 inhibitors (dapagliflozin, empagliflozin) — now recommended; reduce HF hospitalizations
Diuretics for volume/symptom control
Aggressive management of underlying comorbidities (HTN, DM, AF, obesity)

Device Therapy

Device	Indication
ICD (implantable cardioverter-defibrillator)	EF ≤ 35% despite GDMT ≥ 3 months; NYHA II–III; ≥ 1 year survival expected
CRT (cardiac resynchronization therapy)	EF ≤ 35% + LBBB + QRS ≥ 150 ms; NYHA II–IV
CRT-D	Combines CRT + ICD
LVAD	Bridge to transplant or destination therapy in advanced HF
Heart transplantation	End-stage HF; NYHA III–IV refractory to all therapy

Complications

Sudden cardiac death (ventricular arrhythmias)
Cardiogenic shock
Renal failure (cardiorenal syndrome)
Hepatic congestion / cardiac cirrhosis
Pulmonary hypertension
Thromboembolic events (stroke, DVT/PE) — especially in AF
Malnutrition / cardiac cachexia

Prognosis

5-year mortality ~50% overall; worse than many cancers
HFrEF mortality has improved substantially with GDMT (especially the addition of SGLT2i and ARNi)
Poor prognostic markers: low EF, elevated BNP, renal dysfunction, hyponatremia, NYHA Class IV, recurrent hospitalizations
HFpEF prognosis approaches HFrEF in severity but fewer proven therapies exist

Sources: ESC 2023 Focused Update – Diagnosis and Treatment of Acute and Chronic Heart Failure (p. 5); ESC Guidelines – Management of Cardiovascular Disease in Patients with Diabetes (p. 44); clinical imaging from PMC Clinical VQA dataset.

This is a shared conversation. Sign in to Orris to start your own chat.